Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Japan Tobacco Licenses Osteoporosis Drug To Merck

This article was originally published in PharmAsia News

You may also be interested in...



Asia Partnerships Critical To Big Pharma’s Drying Pipelines, Merck Exec Tells Bio Korea (Part 2 of 2)

[Editor's note: This is part two of a two-part story from Bio Korea; part one was published in PharmAsia News, Oct. 12, 2008.]

Asia Partnerships Critical To Big Pharma’s Drying Pipelines, Merck Exec Tells Bio Korea (Part 2 of 2)

[Editor's note: This is part two of a two-part story from Bio Korea; part one was published in PharmAsia News, Oct. 12, 2008.]

MedImmune Gains Anti-CD28 Biologic In Deal With Japan Tobacco

MedImmune is bolstering its research pipeline for treatments targeting inflammatory diseases, announcing its second licensing deal this month for technology in the therapeutic class. Under the latest deal with Japan Tobacco, announced Dec. 28, the company intends to develop a monoclonal antibody targeting CD28 receptor pathways for treatment of inflammatory diseases

UsernamePublicRestriction

Register

SC143406

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel